MLD to attend Canadian Conference on Dementia

MLD will once again be attending the Canadian Conference on Dementia (CCD) November 2-4th in Toronto. The conference highlights clinically relevant, cutting-edge dementia research from Canada and around the world. In additional to learning about the latest research and clinical management strategies in dementia, the conference provides an opportunity to meet with Canadian dementia researchers and clinicians. This information and these interactions will be instrumental as MLD completes its Phase I adult safety study with lead plasmalogen precursor PPI-1011 for the treatment of RCDP and Alzheimer’s disease, after which it anticipates beginning enrolment of a Phase IIa clinical trial.